|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Incyte insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Incyte insider buys are important for investors to follow.
Date | Insider | Price | Amount |
3-10-2022 Insider Buy |
BROS. Advisors LP Baker Director and >10% Owner |
$72.24
CAGR »
|
$28,107,769.68 389,080 shares |
2-22-2022 Insider Buy |
BROS. Advisors LP Baker Director and >10% Owner |
$67.96
CAGR »
|
$35,734,889.94 525,804 shares |
2-14-2022 Insider Buy |
BROS. Advisors LP Baker Director and >10% Owner |
$66.91
CAGR »
|
$106,952,404.22 1,598,374 shares |
12-17-2021 Insider Buy |
BROS. Advisors LP Baker
|
$72.43
CAGR »
|
$115,558,899.97 1,595,519 shares |
2-23-2021 Insider Buy |
Herve Hoppenot Chairman / CEO |
$77.37
CAGR »
|
$1,000,007.25 12,925 shares |
5-28-2020 Insider Buy |
BROS. Advisors LP Baker Director and >10% Owner |
$102.55
CAGR »
|
$205.10 2 shares |
11-8-2018 Insider Buy |
Jean Jacques Bienaime Director |
$68.77
CAGR »
|
$68,765.00 1,000 shares |
5-2-2018 Insider Buy |
Herve Hoppenot Chairman / CEO |
$60.94
CAGR »
|
$914,100.00 15,000 shares |
9-8-2017 Insider Buy |
BROS. Advisors LP Baker Director and >10% Owner |
$132.00
CAGR »
|
$13,200,000.00 100,000 shares |
5-31-2017 Insider Buy |
Jean Jacques Bienaime Director |
$131.80
CAGR »
|
$65,900.00 500 shares |
5-15-2017 Insider Buy |
Jean Jacques Bienaime Director |
$115.00
CAGR »
|
$57,500.00 500 shares |
4-28-2017 Insider Buy |
Jean Jacques Bienaime Director |
$124.26
CAGR »
|
$62,130.00 500 shares |
4-13-2017 Insider Buy |
Jean Jacques Bienaime Director |
$139.66
CAGR »
|
$139,660.00 1,000 shares |
4-7-2017 Insider Buy |
Jean Jacques Bienaime Director |
$139.48
CAGR »
|
$139,480.00 1,000 shares |
3-17-2016 Insider Buy |
Julian Baker Director and >10% Owner |
$63.98
CAGR »
|
$51,184,193.94 800,000 shares |
2-25-2016 Insider Buy |
Julian Baker Director and >10% Owner |
$70.79
CAGR »
|
$4,550,986.83 64,290 shares |
2-12-2016 Insider Buy |
Julian Baker Director and >10% Owner |
$63.53
CAGR »
|
$143,029,696.12 2,251,427 shares |
2-16-2016 Insider Buy |
Julian Baker Director and >10% Owner |
$69.87
CAGR »
|
$61,983,797.34 887,165 shares |
12-17-2012 Insider Buy |
Richard U. De Schutter Director |
$16.11
CAGR »
|
$724,950.00 45,000 shares |
1-19-2012 Insider Buy |
Paul A. Brooke Director |
$17.70
CAGR »
|
$884,750.00 50,000 shares |
1-13-2012 Insider Buy |
Baker Brothers Life Sciences Capital (GP), LLC Director and >10% Owner |
$16.37
CAGR »
|
$8,892,707.23 543,239 shares |
1-13-2012 Insider Buy |
14159 capital (GP), LLC Director and >10% Owner |
$16.37
CAGR »
|
$239,408.30 14,625 shares |
12-9-2011 Insider Buy |
14159 capital (GP), LLC Director and >10% Owner |
$13.37
CAGR »
|
$144,744.08 10,827 shares |
12-9-2011 Insider Buy |
Baker Brothers Life Sciences Capital (GP), LLC Director and >10% Owner |
$13.37
CAGR »
|
$5,394,595.05 403,521 shares |
12-7-2011 Insider Buy |
Baker Brothers Life Sciences Capital (GP), LLC Director and >10% Owner |
$13.75
CAGR »
|
$21,376,451.07 1,555,134 shares |
12-7-2011 Insider Buy |
14159 capital (GP), LLC Director and >10% Owner |
$13.75
CAGR »
|
$572,097.19 41,620 shares |
12-1-2011 Insider Buy |
Baker Brothers Life Sciences Capital (GP), LLC Director and >10% Owner |
$13.13
CAGR »
|
$31,588,303.93 2,406,179 shares |
12-1-2011 Insider Buy |
14159 capital (GP), LLC Director and >10% Owner |
$13.04
CAGR »
|
$668,776.38 51,270 shares |
11-17-2011 Insider Buy |
Wendy L. Dixon Director |
$13.40
CAGR »
|
$100,496.53 7,500 shares |
Also See: Institutional Holders of INCY
Also See: SEC filings
Below we present the annualized performance delivered by Incyte stock since 3-10-2022 (the date of the most recent
insider purchase). The performance of the investment from the time Incyte insider buying occurred is the ultimate
test of whether insiders were right about INCY being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/11/2022 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$73.94 |
|
End price/share: |
$52.82 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-28.56% |
|
Average Annual Total Return: |
-14.77% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7,144.29 |
|
Years: |
2.10 |
|
Incyte Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Incyte insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding INCY
|
|